TSC2 c.4046_4047del ;(p.A1349Gfs*64)

Variant ID: 16-2134266-ACG-A

NM_000548.3(TSC2):c.4046_4047del;(p.A1349Gfs*64)

This variant was identified in 1 publication

View GRCh38 version.




Publications:


Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Adib, Elio E; Klonowska, Katarzyna K; Giannikou, Krinio K; Do, Khanh T KT; Pruitt-Thompson, Solida S; Bhushan, Ketki K; Milstein, Matthew I MI; Hedglin, Jennifer J; Kargus, Katherine E KE; Sholl, Lynette M LM; Tsuji, Junko J; Hyman, David M DM; Sisk, Anne A; Shapiro, Geoffrey I GI; Vargas, Hebert A HA; Harding, James J JJ; Voss, Martin H MH; Iyer, Gopa G; Kwiatkowski, David J DJ
Publication Date: 2021-07-15

Variant appearance in text: TSC2: 4046_4047del; Ala1349Glyfs*64
PubMed Link: 33727259
Variant Present in the following documents:
  • Main text
View BVdb publication page